Compare Gilead Sciences, Inc. (GILD) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Yum! Brands, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.92 (market cap $168.35B), while Yum! Brands, Inc. trades at $148.98 (market cap $39.50B). The key difference: Gilead Sciences, Inc. is far larger — about 4.3× Yum! Brands, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | YUM | |
|---|---|---|
Market Cap | $168.35B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $168.16 |
52-Week Low | $110.56 | $138.21 |
Enterprise Value | $191.42B | $51.10B |
Dividend Yield | 2.42% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
YUM Brands trades at $148.91, up 2.46% with recent earnings beats offset by food safety concerns. Technical indicators show bearish momentum with support at $141, while fundamentals reveal strong revenue growth to $8.21B in 2025 and net income of $1.56B. The company recently completed the $1.2B sale of Pizza Hut China, streamlining operations amid cyclospora outbreak impacts on Taco Bell sales.
YUM presents a mixed outlook with 37% analyst buy ratings and $174.60 price target suggesting 17% upside, but faces near-term headwinds from food safety investigations and consumer sentiment. Long-term growth depends on KFC/Taco Bell execution and digital strategy success amid elevated debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
